Drug intelligence / Profile preview

GPX-003

Development stage: Preclinical
Lead developer: Genprex
Modality: Gene Therapies
Administration: Parenteral

Overview

GPX-003 is a preclinical gene therapy candidate being developed by Genprex for the treatment of Type 2 diabetes. Licensed from the University of Pittsburgh, the therapy utilizes an adeno-associated virus (AAV) vector to deliver the transcription factors Pancreatic and duodenal homeobox 1 (Pdx1) and MAF bZIP transcription factor A (MafA) under the control of an insulin promoter. The primary mechanism of action is the rejuvenation of exhausted pancreatic beta cells to restore endogenous insulin production. GPX-003 is currently undergoing preclinical evaluation in non-human primate (NHP) models to support its advancement toward clinical trials.

Targets

MAFA (V-maf musculoaponeurotic fibrosarcoma oncogene homolog A)PDX1 (Pancreas/duodenum homeobox protein 1)

Beyond the preview

Go deeper on GPX-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GPX-003.

Explore the full profile